These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 17884394

  • 1. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles.
    Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A.
    Eur J Pharm Sci; 2007 Dec; 32(4-5):278-90. PubMed ID: 17884394
    [Abstract] [Full Text] [Related]

  • 2. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
    Borges O, Cordeiro-da-Silva A, Tavares J, Santarém N, de Sousa A, Borchard G, Junginger HE.
    Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
    [Abstract] [Full Text] [Related]

  • 3. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
    Borges O, Silva M, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A.
    Int Immunopharmacol; 2008 Dec 20; 8(13-14):1773-80. PubMed ID: 18801462
    [Abstract] [Full Text] [Related]

  • 4. Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers.
    Borges O, Borchard G, de Sousa A, Junginger HE, Cordeiro-da-Silva A.
    Int J Pharm; 2007 Jun 07; 337(1-2):254-64. PubMed ID: 17317051
    [Abstract] [Full Text] [Related]

  • 5. Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
    Prego C, Paolicelli P, Díaz B, Vicente S, Sánchez A, González-Fernández A, Alonso MJ.
    Vaccine; 2010 Mar 19; 28(14):2607-14. PubMed ID: 20096389
    [Abstract] [Full Text] [Related]

  • 6. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
    Ma R, Du JL, Huang J, Wu CY.
    Biochem Biophys Res Commun; 2007 Sep 21; 361(2):537-42. PubMed ID: 17662694
    [Abstract] [Full Text] [Related]

  • 7. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
    Khatri K, Goyal AK, Gupta PN, Mishra N, Vyas SP.
    Int J Pharm; 2008 Apr 16; 354(1-2):235-41. PubMed ID: 18182259
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
    Jaganathan KS, Vyas SP.
    Vaccine; 2006 May 08; 24(19):4201-11. PubMed ID: 16446012
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the effects of biodegradable nanoparticles on a vaccine delivery system using AFM, SEM, and TEM.
    Kim BG, Kang IJ.
    Ultramicroscopy; 2008 Sep 08; 108(10):1168-73. PubMed ID: 18554804
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen.
    Song ES, Park SA, Kim SH, Cho YJ, Ahn BY, Ahn BC, Lee NG.
    FEMS Immunol Med Microbiol; 2007 Dec 08; 51(3):496-504. PubMed ID: 17877731
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJ, Jiskoot W.
    Vaccine; 2007 Jan 02; 25(1):144-53. PubMed ID: 16973248
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B.
    Jain S, Singh P, Mishra V, Vyas SP.
    Immunol Lett; 2005 Oct 15; 101(1):41-9. PubMed ID: 15869802
    [Abstract] [Full Text] [Related]

  • 19. Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine.
    Nyström J, Cardell K, Björnsdottir TB, Fryden A, Hultgren C, Sällberg M.
    Vaccine; 2008 Nov 05; 26(47):5967-72. PubMed ID: 18804140
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of immune responses to hepatitis B vaccine in immunodepressed mice by CpG oligodeoxynucleotide.
    Qin WB, Jiang JW, Yang N, Chen QE, Wang YF, Wei XC, Ou RQ.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov 05; 20(6):647-50. PubMed ID: 15555425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.